A new drug, which proved heart and kidney protection effects in chronic kidney disease (CKD) patients accompanying type-2 diabetes, has arrived in Korea to counter well-established SGLT-2 inhibitors.On Tuesday, the Ministry of Food and Drug Safety authorized the use of Bayer’s Kerendia (ingredient:
LegoChem Bioscience said that it would start the operation of AntibodyChem Biosciences (ACB), its U.S. subsidiary in Boston.The company established ACB to develop global new drugs based on its antibody-drug conjugate (ADC) platform technology. ACB will lead global clinical development by joining the
Ferring’s Rekovelle (follitropin delta), a treatment to promote egg production in ovaries, became reimbursable when used in combination with human menopausal gonadotropin (hMG) in women receiving in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).Ferring Korea said Rekovelle got
Hanmi Pharmaceutical said that Aptose Biosciences, its American partner, has received orphan drug designation (ODD) for HM43239, an acute myeloid leukemia (AML) treatment, from the U.S. Food and Drug Administration.The company had licensed out the treatment to Aptose in November.Under the deal, Hanm
BMS’ anemia treatment Reblozyl (ingredient: luspatercept) arrived in the Korean market only two and a half years after the company completed drug development in the U.S.The Ministry of Food and Drug Safety authorized Reblozyl to treat adult anemia patients who failed an erythropoiesis-stimulating ag
Forxiga (dapagliflozin) and Jardiance (empagliflozin), the two representative SGLT-2 inhibitors, are competing not only in diabetes but cardio and renal diseases.On Thursday, AstraZeneca said Forxiga met the primary endpoint in a large-scale global phase 3 study, DELIVER, reducing the risk of cardio
Shionogi, a Japanese pharmaceutical company, halted its phase 2/3 trial of S-217622, an oral Covid-19 treatment candidate, in the Philippines.According to Philippine Health Research Registry on Monday, Shionogi updated the S-217622 phase 2/3 clinical trial status in the Philippines to “terminated” a
HLB said that its U.S. subsidiary Elevar Therapeutics has started marketing Apealea, an ovarian cancer treatment, in Germany after listing the drug on Gelbe Liste, a German drug distribution website.Elevar acquired the global rights for the drug from Vivesto, the original developers, in March 2020.
AstraZeneca (AZ) and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan), the second-generation antibody-drug conjugate (ADC) that showed superiority to Roche’s Kadcyla in HER2-positive breast cancer treatment, received U.S. approval for patients with metastatic HER2-positive breast cancer after one p
Hugel said on Friday that it received a clinical study report (CSR) on the phase 1 trial of HG102, a lidocaine-containing liquid botulinum toxin (BTX), on Wednesday.HG102 is made into liquid from the existing BTX in a freeze-dried powder form. It contains lidocaine hydrogen chloride, a local anesthe
The Ministry of Food and Drug Safety (MFDS) and the pharmaceutical industry are wrangling over whether the nation should allow the indirect export of botulinum toxin (BTX) products through agencies.Industry officials raised concerns that the latest controversy, sparked by the regulator’s detection o
Yuyu Pharmaceutical presented a poster study for YP-P10, its new dry eye syndrome treatment, during the 2022 ARVO (Association for Research in Vision and Ophthalmology) conference.ARVO, established in 1928, is the world's largest ophthalmology society and has 12,000 research members from over 75 cou
Sam Chun Dang Pharm has been clarifying the discussion with a Chinese pharmaceutical firm over licensing out a diabetic drug candidate repeatedly for a year. Attention is on whether the two will ink a final deal and when it will happen.“We are discussing a deal with China’s Tonghua Dongbao Pharmaceu
Novo Nordisk Korea said Monday that the Ministry of Food and Drug Safety approved Rybelsus, the world's first oral GLP-1 analog treatment for type 2 diabetes.The treatment, which comes in three dosages – 3mg, 7mg, and 14mg- is a semaglutide drug that patients with insufficient control over their typ
Chong Kun Dang said Monday it has launched Cantabell A, a three-agent combination treatment for hypertension and dyslipidemia.It is the first combination therapy in Korea to combine the high blood pressure drug angiotensin II receptor blocker (ARB) candesartan, calcium channel blocker (CCB) amlodipi
Medytox said Tuesday that the U.S. International Trade Commission (ITC) has decided to investigate the company's complaint about Hugel, Hugel America, Hugel’s local offshoot, and Croma Pharma, Hugel's global partner.Medytox submitted a complaint to the ITC in April, claiming that Hugel developed bot
Gilead Science Korea said its hepatitis B treatment Vemlidy (Ingredient: tenofovir alafenamide) started receiving expanded health insurance coverage for treating patients with decompensated cirrhosis and hepatitis B with hepatocellular carcinoma on Sunday.The government expanded the reimbursement st
Aphrodite Acquisition Holdings has completed the stock purchase agreement (SPA) with Leguh Issuer Designated Activity Company (LIDAC), the former largest shareholder of Hugel, a botulinum toxin product maker.Hugel’s shareholders approved it at an extraordinary meeting at the company headquarters in
SK Bioscience’s recent application for marketing approval for SKYCovione (code name: GBP510), a Covid-19 vaccine, is drawing much attention to when it will win the nod and whether the vaccine will achieve commercial success.Pharmaceutical industry watchers said SKYCovione’s success would hinge on it
GC said it has entered into a development and option agreement with Acuitas Therapeutics, a Canada-based company, by licensing in the latter's lipid nanoparticle (LNP) delivery system.Under the accord, GC will use up to four LNP technologies owned by Acuitas to develop messenger RNA (mRNA) vaccines